ArticlePloS one2014
Safety and Immunogenicity of a Mycoplasma ovipneumoniae bacterin for domestic sheep (Ovis aries).
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Aoudad (Ammotragus lervia) as disease reservoirs for bighorn sheep (Ovis canadensis): experimental and epidemiological evidence.Scientific reports · 2026Article
- Outcomes of Selective Removals for Control of Pneumonia in a Bighorn Sheep Metapopulation.Ecology and evolution · 2025Article
- Fatal interactions: pneumonia in bighorn lambs following experimental exposure to carriers ofJournal of clinical microbiology · 2025Article
- Pathogen delivery route impacts disease severity in experimental Mycoplasma ovipneumoniae infection of domestic lambs.Veterinary research · 2025Article
- Upper respiratory tract detection of Mycoplasma ovipneumoniae employing nasopharyngeal swabs.BMC veterinary research · 2024Article
- High-throughput rapid amplicon sequencing for multilocus sequence typing ofFrontiers in veterinary science · 2024Article
- Article
- Antibiotic treatment ofThe Canadian veterinary journal = La revue veterinaire canadienne · 2023Article
- Article
- Review
- Development of a real-time PCR assay for detection and differentiation of Mycoplasma ovipneumoniae and a novel respiratory-associated Mycoplasma species in domestic sheep and goats.Transboundary and emerging diseases · 2022Article
- Bighorn sheep show similar in-host responses to the same pathogen strain in two contrasting environments.Ecology and evolution · 2022Article
- Disease Ecology of a Low-VirulenceAnimals : an open access journal from MDPI · 2022Article
- Vaccines for Mycoplasma Diseases of Small Ruminants: A Neglected Area of Research.Pathogens (Basel, Switzerland) · 2022Review
- Using transcriptomics to predict and visualize disease status in bighorn sheep (Conservation physiology · 2022Article
- Natural history of a bighorn sheep pneumonia epizootic: Source of infection, course of disease, and pathogen clearance.Ecology and evolution · 2021Article
- Impact ofPeerJ · 2021Article
- Mycoplasma bovis Infections in Free-Ranging Pronghorn, Wyoming, USA.Emerging infectious diseases · 2020Article
- Removal of chronicEcology and evolution · 2020Article
- Loop-mediated isothermal amplification-lateral-flow dipstick (LAMP-LFD) to detect Mycoplasma ovipneumoniae.World journal of microbiology & biotechnology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMortality from epizootic pneumonia is hindering re-establishment of bighorn sheep populations in western North America. Mycoplasma ovipneumoniae, a primary agent of this disease, is frequently carried asymptomatically by the domestic sheep and goats that constitute the reservoir of this agent for transmission to bighorn sheep. Our long-term objective is to reduce the risk of M. ovipneumoniae infection of bighorn sheep; one approach to this objective is to control the pathogen in its reservoir hosts.
methodsThe safety and immunogenicity of M. ovipneumoniae for domestic sheep was evaluated in three experimental immunization protocols: 1) live M. ovipneumoniae (50 ug protein); 2) killed M. ovipneumoniae (50 ug whole cell protein) in oil adjuvant; and 3) killed M. ovipneumoniae (250 ug whole cell protein) in oil adjuvant. Immunogenicity was assessed by two serum antibody measures: competitive enzyme-linked immunosorbent assay (cELISA) (experiments 1-3) and serum growth inhibition (Experiment 3). Passive immunogenicity was also assessed in the third experiment using the same assays applied to blood samples obtained from the lambs of immunized ewes. RESULTS AND
conclusionsAdverse reactions to immunization were generally minor, but local reactions were regularly observed at immunization sites with bacterins in oil adjuvants. No evidence of M. ovipneumoniae specific antibody responses were observed in the first or second experiments and no resistance to colonization was observed in the first experiment. However, the ewes in the third experiment developed strong cELISA serum antibody responses and significant serum M. ovipneumoniae inhibition activity, and these responses were passively transferred to their lambs. The results of these trials indicate that immunization with relatively large antigenic mass combined with an adjuvant is capable of inducing strong active antibody responses in ewes and passively immunizing lambs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.